Candel Therapeutics (CADL) News Today $5.12 -0.24 (-4.38%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CADL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Bank of America Corp DE Buys 44,952 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)Bank of America Corp DE grew its stake in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 205.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,811 shares of the company's stock after acquiringJune 11 at 3:10 AM | marketbeat.comCandel Therapeutics adds biotech veteran Maha Radhakrishnan to BoardJune 6, 2025 | proactiveinvestors.comCandel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsJune 6, 2025 | globenewswire.comCandel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate CancerMay 30, 2025 | msn.comCandel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On?May 28, 2025 | benzinga.comCandel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term BuyMay 28, 2025 | msn.comCandel Therapeutics get FDA's RMAT designation for prostate cancer therapyMay 28, 2025 | proactiveinvestors.comCandel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate CancerMay 28, 2025 | globenewswire.comCandel Therapeutics: CAN-2409's Promising Progress Deserves An UpgradeMay 27, 2025 | seekingalpha.comCandel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO PresentationMay 27, 2025 | globenewswire.comCandel’s phase 3 trial for prostate cancer therapy shows promiseMay 24, 2025 | investing.comCandel Therapeutics to Present Positive Phase 3 Clinical Trial Results of CAN-2409 for Prostate Cancer at ASCO 2025May 24, 2025 | nasdaq.comCandel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025May 23, 2025 | proactiveinvestors.comCandel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025May 23, 2025 | insidermonkey.comCandel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025May 22, 2025 | globenewswire.comMaven Securities LTD Invests $449,000 in Candel Therapeutics, Inc. (NASDAQ:CADL)Maven Securities LTD bought a new stake in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 51,731 shares of the company's stock, valued at approximately $449,0May 16, 2025 | marketbeat.comCandel Therapeutics (NASDAQ:CADL) Announces Quarterly Earnings Results, Beats Expectations By $0.37 EPSCandel Therapeutics (NASDAQ:CADL - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported $0.13 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.37.May 15, 2025 | marketbeat.comCardell Flat on Q1May 13, 2025 | baystreet.caCandel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More BullishMay 13, 2025 | msn.comCandel Therapeutics posts Q1 profit, eyes 2026 BLA submission for prostate cancer drugMay 13, 2025 | proactiveinvestors.comCandel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsMay 13, 2025 | globenewswire.comCandel Therapeutics (CADL) Expected to Announce Earnings on TuesdayCandel Therapeutics (NASDAQ:CADL) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-13-candel-therapeutics-inc-stock/)May 8, 2025 | marketbeat.comBraidwell LP Invests $13.89 Million in Candel Therapeutics, Inc. (NASDAQ:CADL)Braidwell LP acquired a new stake in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,600,000 shares of the company's stock, valued at approximately $13,888,000. BMay 8, 2025 | marketbeat.comCandel Therapeutics to Present at Upcoming Investor ConferencesMay 6, 2025 | finance.yahoo.comBaker BROS. Advisors LP Takes $25.88 Million Position in Candel Therapeutics, Inc. (NASDAQ:CADL)Baker BROS. Advisors LP acquired a new position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 2,981,983 shares of the company's stock, valued at approximately $25,May 6, 2025 | marketbeat.comAcorn Capital Advisors LLC Takes $16.84 Million Position in Candel Therapeutics, Inc. (NASDAQ:CADL)Acorn Capital Advisors LLC acquired a new position in shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,939,644 shares of the compaMay 4, 2025 | marketbeat.comBirchview Capital LP Makes New Investment in Candel Therapeutics, Inc. (NASDAQ:CADL)Birchview Capital LP purchased a new position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 60,000 shares of the company's stock, valued at appApril 28, 2025 | marketbeat.comCandel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025April 23, 2025 | globenewswire.comCandel Therapeutics, Inc. (NASDAQ:CADL) Sees Significant Growth in Short InterestCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 4,470,000 shares, a growth of 29.6% from the March 15th total of 3,450,000 shares. Currently, 12.9% of the company's stock are short sold. Based on an average daily trading volume, of 1,220,000 shares, the short-interest ratio is currently 3.7 days.April 21, 2025 | marketbeat.comPortolan Capital Management LLC Acquires New Position in Candel Therapeutics, Inc. (NASDAQ:CADL)Portolan Capital Management LLC purchased a new stake in shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 753,745 shares of the compApril 16, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Candel Therapeutics (NASDAQ:CADL)HC Wainwright restated a "buy" rating and set a $19.00 target price on shares of Candel Therapeutics in a research report on Friday.April 13, 2025 | marketbeat.comCandel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade ...April 3, 2025 | seekingalpha.comCandel Therapeutics announces publication of Phase 1b trial data on CAN-2409April 2, 2025 | markets.businessinsider.comCandel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409April 1, 2025 | proactiveinvestors.comCandel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma PatientsApril 1, 2025 | globenewswire.comCandel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMIMarch 29, 2025 | proactiveinvestors.comCandel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMIMarch 29, 2025 | proactiveinvestors.comCandel Therapeutics announces final survival data from CAN-2409 trialMarch 27, 2025 | markets.businessinsider.comCandel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trialMarch 26, 2025 | proactiveinvestors.comCandel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) TreatmentMarch 26, 2025 | globenewswire.comCandel Therapeutics, IDEA Pharma announce strategic partnershipMarch 20, 2025 | markets.businessinsider.comCandel Therapeutics, Inc. (NASDAQ:CADL) Insider Charles Schoch Sells 5,000 SharesCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) insider Charles Schoch sold 5,000 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $8.83, for a total transaction of $44,150.00. Following the completion of the sale, the insider now directly owns 38,038 shares of the company's stock, valued at approximately $335,875.54. The trade was a 11.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.March 20, 2025 | marketbeat.comSeshu Tyagarajan Sells 31,278 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) StockCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) CTO Seshu Tyagarajan sold 31,278 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $8.82, for a total value of $275,871.96. Following the completion of the transaction, the chief technology officer now owns 85,512 shares in the company, valued at approximately $754,215.84. The trade was a 26.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.March 20, 2025 | marketbeat.comCandel Therapeutics partners with IDEA Pharma on commercialization of lead asset CAN-2409March 20, 2025 | proactiveinvestors.comCandel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409March 20, 2025 | globenewswire.comInsider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 5,000 Shares of StockMarch 20, 2025 | insidertrades.comCandel Therapeutics (CADL) Projected to Post Earnings on ThursdayCandel Therapeutics (NASDAQ:CADL) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comCandel Therapeutics, Inc. (NASDAQ:CADL) is Halter Ferguson Financial Inc.'s 6th Largest PositionHalter Ferguson Financial Inc. grew its position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 123.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 681,334 shares of the company's stock after buying an additionaMarch 19, 2025 | marketbeat.comCandel Therapeutics appoints Jaffee to RABMarch 18, 2025 | msn.comCandel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory BoardMarch 18, 2025 | markets.businessinsider.com Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address CADL Media Mentions By Week CADL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CADL News Sentiment▼1.310.88▲Average Medical News Sentiment CADL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CADL Articles This Week▼23▲CADL Articles Average Week Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AUPH News Today CVAC News Today MLYS News Today PAHC News Today RCUS News Today WVE News Today SNDX News Today COLL News Today ELVN News Today SYRE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CADL) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CADL Stock Free CADL Stock Alerts